Enoxacin Enhances Pre-miRNA Processing to Treat ALS
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for motor neuron diseases, such as ALS, have limited efficacy, and there is a need for innovative therapeutic approaches that target the altered microRNA metabolism associated with these conditions.
Innovation Solution
Administering a therapeutically effective amount of an agent capable of enhancing the processing of pre-miRNA, specifically using enoxacin to upregulate miRNA processing pathways, which are impaired in motor neuron diseases, to restore normal miRNA levels and slow disease progression.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Duration of action of moving object
If current treatments for motor neuron diseases are used, then patient survival is extended slightly, but disease progression continues and efficacy remains limited
Solution Approach 1:
The patent changes the therapeutic parameter from general neuroprotection to specific miRNA processing enhancement. By using enoxacin to target the processing of pre-miRNA to mature miRNA conversion, the treatment addresses the specific molecular defect in ALS (impaired miRNA processing) rather than providing general symptomatic relief, thereby improving both efficacy and survival outcomes
Solution Approach 2:
Enoxacin acts as an intermediary compound that restores normal miRNA processing function. The drug mediates the conversion between pre-miRNA and mature miRNA, correcting the molecular imbalance caused by ALS pathology. This intermediary approach allows restoration of endogenous regulatory mechanisms rather than introducing entirely new therapeutic molecules
2Reliability
If miRNA processing is enhanced using enoxacin, then mature miRNA levels are restored and disease progression slows, but the complexity of targeting specific molecular pathways increases
Solution Approach 1:
The treatment leverages the body's own miRNA processing machinery and endogenous pre-miRNA substrates. By enhancing the natural processing pathway with enoxacin, the system uses self-service mechanisms rather than requiring complex external delivery systems or synthetic miRNA replacements. The endogenous components perform the therapeutic function when properly activated
Solution Approach 2:
Enoxacin targets a universal processing pathway that applies to all miRNAs, rather than requiring separate treatments for individual miRNA deficiencies. The drug enhances the general miRNA processing machinery (Drosha, Dicer complexes), providing broad-spectrum therapeutic effects across multiple miRNA pathways simultaneously, thereby simplifying the treatment approach
3Ease of operation
If conventional ALS treatments are administered, then symptom management is provided, but the underlying altered microRNA metabolism is not addressed
Solution Approach 1:
The patent takes preliminary action by addressing the root metabolic defect (impaired miRNA processing) before symptoms fully manifest or progress. By correcting the miRNA processing imbalance early in the disease course, the treatment prevents downstream pathological effects rather than merely managing symptoms after they occur. This preliminary correction of metabolic dysfunction provides both preventive and therapeutic benefits
Data Source
Figure 1A~1C
Figure 2A~2H
Figure 3
AI summary
A method of treating a motor neuron disease (MND) in a subject in need thereof is provided. The method comprising administering to the subject a therapeutically effective amount of an agent capable of enhancing processing of a pre-mi RNA, thereby treating the MND in the subject.